Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin in pediatric solid tumors and Ewing sarcoma
NCT05734066Phase 2Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- May 2023
- Primary completion
- Jan 2028
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 2 trial of lurbinectedin in Ewing sarcoma, sponsored by Jazz Pharmaceuticals plc. Started May 2023; status: recruiting.
02
Drugs
lurbinectedin
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT05734066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05734066.